|

HAVN’s Cluster Headache Treatment BETTER Than Mindmed’s? (HAVN CEO Interview)

ByPsychedelic Spotlight

HAVN VS. Mindmed – Whose Cluster Headache Treatment Is Better?

Havn Life Sciences, (CSE: HAVN / OTC: HAVLF / FRA: 5NP) has started to be mentioned more and more on this channel, particularly in our “This Week In Psychedelic Stocks” segment.
In light of HAVN’s recent news that it is entering the cluster headaches segment, we are having a discussion with the company CEO, Tim Moore.

HAVN is focused on standardizing extraction of psychoactive compounds, the development of natural health products, and developing innovative mental health treatment to support brain health and enhance the capabilities of the mind.

Interestingly enough, HAVN Labs is of the first companies to receive permission from Health Canada to work with psilocybin in 2020.

The global functional food market is expected to reach $34.3 Billion USD by 2024, registering a CAGR of 8.04% during the forecast period (2019-2024) and is expected to experience huge demand for Reishi and Cordyceps. This is why HAVN Life has decided to pursue formulations with these mushrooms.

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (HAVN) via digital communications. We have been paid ($1000) .

https://havnlife.com/
CSE: HAVN | OTC: HAVLF | FRA: 5NP

#HAVN #HAVNLifeSciences #Mindmed

Similar Posts

  • Compass Pathways Q4 Earnings Call Highlights [Is CMPS Closing In On MindMed?]

    Listen, Videos

    Hey guys! I promised ya’ll that I will keep you updated on Compass Pathways (NASDAQ: CMPS) earnings call. There has been some pretty interesting developments on the company that I thought I should Bring to your attention. Compass Pathways is one of the psychedelic companies that is the furthest advanced in their clinical trials (Phase IIB to treat TRD). However, I wasn’t aware that they are doing a LOT more. This is quite interesting because in my opinion, CMPS is not a one trick pony anymore and it might as well be in direct competition with my favorite company in this sector (MindMed).

    In this video, we’ll cover:
    1. Compass Pathways’ Financials
    2. Their IP
    3. Therapists Training
    4. Future Projects
    5. Digital Technology

    I hope that this is not going to enrage the MindMed fan boys out there. I just thought that it might be interesting for some of you psychedelic investors.
    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Follow us on social media!
    Instagram: @psychedelicinvestor
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    https://mindmed.co/wp-content/uploads/2020/11/investor-deck.pdf
    https://www.businesswire.com/news/home/20190905005528/en/Usona-Institute-Clinical-Trial-Psilocybin-Major-Depressive

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #CompassPathways #CMPS #MindMed

  • Interview With Rabbi Zac Kamenetz

    Listen, Podcasts

    Founder and CEO of Shefa, and Co-Founder of the Jewish Psychedelic Summit, Rabbi Zac Kamenetz, speaks about the upcoming summit and the connection between Judaism and psychedelics.

  • Can TRYP Therapeutics Treat Chronic Pain and Eating Disorders With Psychedelics? (TRYP / TRYF)

    Listen, Videos

    In today’s episode, we’ll be interviewing CEO and Chairman of TRYP Therapeutics, Greg Mckee. Thus far, this is one of the most informative conversations I’ve had the pleasure of having about the psychedelic industry, the different segments that could be simultaneously tackled, the challenges and opportunities for many of the players in this industry and much more.

    I hope you stay till the end and are able to get some value from this discussion.

    TRYP Therapeutics (CSE: TRYP) (OTC: TRYPF), is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. Some of the diseases TRYP is addressing are: eating disorders and fibromyalgia (chronic widespread pain) .

    TRYP intends to seek approval from FDA to proceed directly into a Phase 2 clinical trial based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803.

    Timestamps:
    0:00 – Intro
    0:40 – TRYP’s mission and Greg Mckee’s personal involvement
    2:59 – Expanding on TRYP’s main molecules: TRP 8802 and TRP 8803
    8:18 – Expanding on TRYP’s flagship programs: Fibromyalgia and Eating Disorder
    14:29 – Clinical trial progress and anticipated start of Phase IIa trials
    18:26 – Anticipated commercialization timelines
    21:34 – TRYP Therapeutics’ competitive advantage
    27:22 – Expected relationship with the traditional pharmaceuticals industry and potential partnerships

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Pertinent links:
    Tryp Therapeutics’ Mission:
    https://tryptherapeutics.com/

    Tryp’s pipeline progress:
    https://tryptherapeutics.com/pipeline/

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (TRYP) via digital communications. We have been paid ($1000) .

    https://tryptherapeutics.com/
    CSE: TRYP | OTC: TRYPF

    #TRYP #TrypTherapeutics #TrypStock

  • Ask A Psychedelic Guide

    Listen, Podcasts

    We welcome back Nick Levich for our “Ask a Psychedelic Professional” series and as part of our “Ask a Psychedelic Guide” episode.